BIBLIOGRAFÍA
1.
Bar-Or, Amit. Inmunology of multiple sclerosis.
Neurologic Clinics 2005, Vol. 23 (1):149-176.
2.
Biogen Idec and Elan. Selective adhesion molecule
(SAM) inhibitors in CNS demyelinating
disorders-Mechanism of action. CD-ROM 2007.
3.
Biogen Idec. The proposed role of the Nrf2
pathway in the pathogenesis of multiple sclerosis. DVD.
2009.
4.
Biogen Idec. MS pathology and interferon beta.
Digital animation. DVD. 2009.
5.
Birnbaum, Albert et al. Combining beta interferon
and atorvastatin may increase disease activity in
multiple sclerosis. Neurology 2008,71;18:1390-1395.
6.
Burt, R. K. et al. Autologous non-myeloablative
haematopoietic stem cell transplantation in
relapsing-remitting multiple sclerosis: a phase I/II
study. Lancet Neurology 2009; 8:244-254.
7.
Correale, Jorge y Garcea, Orlando. Futuras
alternativas de tratamiento.
8.
En: Esclerosis múltiple. Conceptos básicos
y clínicos: 351-365.
Editorial Dunken 2008.
9.
Coles, Alastair et al. Alemtuzumab vs. Interferon
Beta-1a in early multiple sclerosis. The CAMMS223 Trial
Investigator. N. Engl. J. Med 2008;359:1786-801.
10.
Cree, Bruce. Current therapies and role of
emerging small-molecule therapies in MS-Evolving
strategies. www.clinicianschannel/cmscwebcast
11.
Durelli, Luca et al. Inmunomodulatory agents in
multiple sclerosis: clinical trials and therapy. Medlink
Neurology 2007.
12.
EMD Serono. Inmune system abnormalities
implicated in relapsing forms of multiple sclerosis. The
role of T and B cells. DVD. 2009.
13.
Frohman, Elliot et al. Inmunologic Mechanisms of
multiple sclerosis. Neuroimaging Clinics 2008. Vol. 18
(4): 577-588.
14.
Gauthier, Susan et al. Inmunosuppresive therapy
for multiple sclerosis. Neurologic Clinics 2005. Vol. 23
(1): 247-272.
15.
Giovannoni, Gavin et al. Results from the CLARITY
study: A phase III, randomized, double-blind study to
evaluate the safety and efficacy of oral Cladribine in
relapsing-remitting multiple sclerosis (RRMS). 61th
Annual Meeting of the AAN. 2009. Seattle. Washington.
USA.
16.
Hauser, Stephen et al. B-cell depletion with
rituximab in relapsing-remiting multiple sclerosis. New.
Engl. J. Med. 2008, 358;7: 676-688.
17.
Havrdova,Eva et al. Effect of Natalizumab on
clinical and radiological disease activity in multiple
sclerosis: a retrospective analysis of the Natalizumab
safety and efficacy in relapsing-remitting multiple
sclerosis (AFFIRM) study. Lancet Neurology
2009;8:254-60.
18.
Hawker, K et al. Efficacy and safety of rituximab
in patients with primary progressive multiple
sclerosis(PPMS): Results of a randomized double-blind
placebo-controlled multicenter trial. Neurology
2009;72:A254
19.
Kappos, Ludwig. Interferons in multiple
sclerosis. Neurologic Clinics 2005.Vol.23 (1):189-214.
20.
Lassmann, Hans. The pathologic substrate of
magnetic resonance alterations in multiple sclerosis.
Neuroimaging Clinics 2008. V0l.18 (4):563-576
21.
Lauger, Bruno et al. The mechanism of action
behind the lymphocyte-depleting and inmunomodulatory
effects of Cladribine. Poster 108. 61th Annual Meeting
of the AAN. 2009. Seattle. Washington. USA.
22.
Lucchinetti, Claudia. Advances in the
neuropathology of MS. Evolving pathogenic insights.
Continuum 2007,Vol.13 (5):86-116.
23.
Metha, Lahar et al.
Disease Modifyng therapies. Continuum 2007,Vol.13
(5):144-180.
24.
Metz, Luanne, et al. Mynocicline reduces
gadolinium-nehancing magnetis resonance imaging lesions
in multiple sclerosis. Ann. Neurol. 2004. Vol.55
(5):756.
25.
Miller, Aaron. Glatiramer acetate in the
treatment of multiple sclerosis. Neurologic Clinics
2005. Vol. 23 (1): 215-232.
26.
Miller, Aaron. Emerging MS therapies in trial and
development. 60th Annual Meeting of the
American Academy of Neurology. Chicago 2009.
27.
Naismith, Robert et al. Magnetic Resonance
Imaging of MS. Continuum 2007,Vol.13 (5):144-180.
28.
Rose, John et al. Pathogenesis of multiple
sclerosis. Continuum 2007,Vol.13 (5):35-62.
29.
Rudick, Richard et al. Natalizumab plus
interferon beta-1a for relapsing remiting multiple
sclerosis. New Engl. J. Med. 2006, 354:911-923.
30.
Sheridan, James et al. Daclizumab treatment
reduces activated T cells: results from the CHOICE
multiple sclerosis study. Poster 107. 61th Annual
Meeting of the AAN. 2009. Seattle, Washington. USA.
31.
Viglietta, V. et al. CTLA-4Ig treatment in
patients with múltiple sclerosis. An open-label, phase 1
clinical trial. Neurology 2008, 71;12: 917-924.
32.
Ursell, Melanie and O’Connor, Paul. Natalizumab
and other monoclonal antibodies. Neurologic Clinics
2005. Vol. 23 (1): 232-246.
33.
Wingerchuk, Dean. Rational therapeutic
strategies for multiple sclerosis. 60th
Annual Meeting of the American Academy of Neurology.
Chicago 2008.
